Extrawell Pharmaceutical Holdings Ltd (0858) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Extrawell Pharmaceutical Holdings Ltd HK$0.03, price HK$0.07, upside -63.0%, quality 47 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 4, 2026.
How to read this chart
60‑month range HK$0.0260 – HK$0.1760 · the HK$0.0730 price screens above the HK$0.0270 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Oct 4, 2026.
Follow Extrawell Pharmaceutical Holdings in your weekly email
Every Wednesday you see whether Extrawell Pharmaceutical Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Extrawell Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, and sell of pharmaceutical products in the People's Republic of China and Hong Kong.
Show more
Extrawell Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, and sell of pharmaceutical products in the People's Republic of China and Hong Kong. The company manufactures transfer factor oral solution, a dual immune regulator for the treatment of diseases caused by virus infection and weak cellular immune system; Wisk for the treatment of II-III degree of radio-injury of skin, normal common burn, actinic dermatitis, various infectious ulcers, and oral ulcers, as well as for trauma and post operation wound healing; and ZhouBang, a thromboxane synthetase inhibitor to prevent the coagulation of platelets and facilitate relaxation of blood vessels. It is also involved in marketing and distribution of imported pharmaceutical products, including Skin-Cap for the treatment of itching, irritation, redness, and scaly skin issues; and Millibar for the treatment of high blood pressure. In addition, the company develops oral insulin product, which is in clinical trial stage for the treatment of diabetes. Further, the company engages in the provision of agency services and property investment business. Extrawell Pharmaceutical Holdings Limited was incorporated in 1998 and is headquartered in Quarry Bay, Hong Kong.
Stock analysis
Extrawell Pharmaceutical Holdings Ltd (0858) currently trades at HK$0.0730, while our model-based Fair Value estimate is HK$0.0270, 63.0% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Quality & growth
The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Extrawell Pharmaceutical Holdings Ltd reported revenue of HK$51.5M in FY2026 versus HK$73.9M in FY2022, a compound −8.6%/yr. Reported net income was −HK$980M in FY2026.
Key figures
Market cap HK$212M (≈ $27.0M) · P/S ratio 4.11 · EPS (TTM) HK$−0.1900 · Return on equity −114% · Return on assets (EBIT) −1.0% · Operating margin −24.9% · Revenue (TTM) HK$51.5M · Revenue growth (YoY) −9.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 35% below its 52-week high and 24% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −63%, 0858 screens richer than that median.
Fair Value models
Bear HK$0.0270Fair Value HK$0.0270Bull HK$0.0270
Price HK$0.0730 · Upside -63.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−7.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−10.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.2%
Start year 2021 (pandemic). Over 10 years: −9.7% a year
Revenue growth 26 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.4%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−8.9% (2021) → −18.9% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
Compare Extrawell Pharmaceutical Holdings Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 602 stocks
Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation
Quality Score47 · Below median
Fair Value upside−63.0% · Bottom 25%
Profitability
Return on assets−0.6% · Below median
Operating margin (TTM)−24.9% · Bottom 25%
Growth and dividend
Revenue growth−9.0% · Bottom 25%
Balance sheet
Debt / equity0.37× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/B0.07× · Cheapest 25%
P/S (TTM)0.52× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 17
FUTURE (revenue growth)0· sector 24
PAST (return on equity)0· sector 26
HEALTH (low debt)81· sector 96
DIVIDEND (yield)0· sector 31
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Extrawell Pharmaceutical Holdings Ltd (0858) overvalued or undervalued?
As of Oct 4, 2026, our model estimates a fair value of HK$0.0270 versus a price of HK$0.0730, about −63% upside (overvalued).
What is the fair value of 0858?
Our model-based fair value for Extrawell Pharmaceutical Holdings Ltd is HK$0.0270 (as of Oct 4, 2026), built from audited fundamentals. The current price: HK$0.0730.
What is the quality score of 0858?
Extrawell Pharmaceutical Holdings Ltd has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Extrawell Pharmaceutical Holdings Ltd (0858)?
Our model-based price target is the fair value of HK$0.0270 (as of Oct 4, 2026) from 1 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Extrawell Pharmaceutical Holdings Ltd stock forecast for 2026?
Our models put fair value at HK$0.0270, about −63% upside versus a price of HK$0.0730 (overvalued). The calculation is refreshed regularly with new filings.
What is the revenue of Extrawell Pharmaceutical Holdings Ltd (0858)?
Extrawell Pharmaceutical Holdings Ltd reported trailing-twelve-month revenue of about HK$51.5M (latest available figure, as of Oct 4, 2026).
What is the intrinsic value of Extrawell Pharmaceutical Holdings Ltd (0858)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Extrawell Pharmaceutical Holdings Ltd it is HK$0.0270 per share (as of Oct 4, 2026), against a price of HK$0.0730. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Extrawell Pharmaceutical Holdings Ltd stock overvalued or undervalued in 2026?
As of Oct 4, 2026, 0858 trades above its calculated fair value: price HK$0.0730, fair value HK$0.0270, a gap of about −63% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0858?
No. The price is what the market pays today (HK$0.0730); the fair value is what the company's own numbers justify (HK$0.0270). For Extrawell Pharmaceutical Holdings Ltd the two are HK$0.0460 per share apart. That gap is exactly why we show both numbers side by side.
How much is Extrawell Pharmaceutical Holdings Ltd worth?
The market values Extrawell Pharmaceutical Holdings Ltd at about HK$212M (market capitalisation, as of Oct 4, 2026). Per share that is HK$0.0730; our models calculate a fair value of HK$0.0270 per share.
How solid is the balance sheet of Extrawell Pharmaceutical Holdings Ltd (0858)?
Balance-sheet figures for Extrawell Pharmaceutical Holdings Ltd (as of Oct 4, 2026): return on equity −114.3%, debt of 0.37 per unit of equity. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is 0858 from its 52-week high?
Extrawell Pharmaceutical Holdings Ltd trades at HK$0.0730, about 35% below its 52-week high of HK$0.1130 and 24% above the low of HK$0.0590 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.0270 is for.
Which stocks are comparable to Extrawell Pharmaceutical Holdings Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Extrawell Pharmaceutical Holdings Ltd stock attractive at the current price?
The data as of Oct 4, 2026: price HK$0.0730, calculated fair value HK$0.0270 (−63%), Quality Score 47/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0858 calculated?
We run Extrawell Pharmaceutical Holdings Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$0.0270, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.0 % above its aggregate fair value. Extrawell Pharmaceutical Holdings Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Extrawell Pharmaceutical Holdings Ltd (0858)?
The closing price on Oct 2, 2026 was HK$0.0730. Our model-based fair value is HK$0.0270, about −63% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Extrawell Pharmaceutical Holdings Ltd right now?
The price sits above even our optimistic bull case (HK$0.0270). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (47/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Extrawell Pharmaceutical Holdings Ltd
How large is the market capitalisation of Extrawell Pharmaceutical Holdings Ltd (0858)?
The market capitalisation of Extrawell Pharmaceutical Holdings Ltd is HK$212M (≈ $27.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Extrawell Pharmaceutical Holdings Ltd (0858)?
The price-to-sales ratio of Extrawell Pharmaceutical Holdings Ltd is 4.11 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Extrawell Pharmaceutical Holdings Ltd (0858)?
Earnings per share at Extrawell Pharmaceutical Holdings Ltd are HK$−0.1900. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Extrawell Pharmaceutical Holdings Ltd (0858)?
The return on equity (ROE) of Extrawell Pharmaceutical Holdings Ltd is −114% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Extrawell Pharmaceutical Holdings Ltd (0858)?
On an EBIT basis the return on assets of Extrawell Pharmaceutical Holdings Ltd is −1.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Extrawell Pharmaceutical Holdings Ltd (0858)?
The operating margin of Extrawell Pharmaceutical Holdings Ltd is −24.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Extrawell Pharmaceutical Holdings Ltd (0858)?
Revenue at Extrawell Pharmaceutical Holdings Ltd is growing −9.0% versus a year earlier (3y avg −10.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Extrawell Pharmaceutical Holdings Ltd (0858)?
Earnings per share at Extrawell Pharmaceutical Holdings Ltd are growing +12.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Extrawell Pharmaceutical Holdings Ltd (0858) generate?
The free cash flow of Extrawell Pharmaceutical Holdings Ltd is −HK$7.4M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Extrawell Pharmaceutical Holdings Ltd (0858) carry?
The net debt of Extrawell Pharmaceutical Holdings Ltd is HK$58.6M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Extrawell Pharmaceutical Holdings Ltd in the live analysis
One click puts Extrawell Pharmaceutical Holdings Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
